Evidence map›Paper›PMID 42683830›Full record

ArticleCancer control : journal of the Moffitt Cancer Center

Assessing the Capacity of Health Facilities to Deliver Concomitant HPV Vaccination and HPV-Based Cervical Screening Services to Vulnerable Populations - An Implementation Research Protocol.

Isabel Mosquera, Anna Tisler, Arianis Tatiana Ramirez, K Miriam Elfstrom, Joakim Dillner, Claudia Robles, Paula Peremiquel-Trillas, Xavier Bosch, Andrea Gini, Iacopo Baussano and 21 more

Abstract read
In one paragraph

Article in Cancer control : journal of the Moffitt Cancer Center. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Isabel MosqueraEarly Detection, Prevention & Infections Branch, International Agency for Research on Cancer (IARC), Lyon, France.ORCID 0000-0001-8886-6244
Anna TislerEarly Detection, Prevention & Infections Branch, International Agency for Research on Cancer (IARC), Lyon, France.
Arianis Tatiana RamirezEarly Detection, Prevention & Infections Branch, International Agency for Research on Cancer (IARC), Lyon, France.ORCID 0000-0002-8317-0130
K Miriam ElfstromCenter for Cervical Cancer Elimination, Department of Clinical Sciences, Interventions & Technologies, Karolinska Institutet, Stockholm, Sweden.
Joakim DillnerCenter for Cervical Cancer Elimination, Department of Clinical Sciences, Interventions & Technologies, Karolinska Institutet, Stockholm, Sweden.
Claudia RoblesCancer Epidemiology Research Programme, Catalan Institute of Oncology (ICO), Barcelona, Spain.
Paula Peremiquel-TrillasCancer Epidemiology Research Programme, Catalan Institute of Oncology (ICO), Barcelona, Spain.
Xavier BoschCancer Epidemiology Research Programme, Catalan Institute of Oncology (ICO), Barcelona, Spain.
Andrea GiniEarly Detection, Prevention & Infections Branch, International Agency for Research on Cancer (IARC), Lyon, France.
Iacopo BaussanoEarly Detection, Prevention & Infections Branch, International Agency for Research on Cancer (IARC), Lyon, France.
Marc BardouUniversité Bourgogne Europe, CHU Dijon Bourgogne, Centre d' Investigation Clinique 1432 unité Plurithématique, Dijon, France.
Amir HassineUniversité Bourgogne Europe, CHU Dijon Bourgogne, Centre d' Investigation Clinique 1432 unité Plurithématique, Dijon, France.
Carine FrancCESP, Team SPR-I (Primary Care, Prevention and Women´s Health) Inserm UMR 1018, University Paris Saclay, University Versailles Saint Quentin, Villejuif, France.ORCID 0000-0001-7166-6895
Gwen MenvielleCancer survivorship, University Paris Saclay, University Versailles Saint Quentin, Gustave Roussy, Inserm, CESP, Villejuif, France.
Mette TranbergUNICCA, Department of Public Health Programmes, Regionshospitalet Randers, Aarhus, Denmark.
Ann-Line AxelsenUNICCA, Department of Public Health Programmes, Regionshospitalet Randers, Aarhus, Denmark.ORCID 0009-0007-3182-8790
Pia KirkegaardUNICCA, Department of Public Health Programmes, Regionshospitalet Randers, Aarhus, Denmark.
Berit AndersenUNICCA, Department of Public Health Programmes, Regionshospitalet Randers, Aarhus, Denmark.
Lone Kjeld PetersenDepartment of Gynecology and Obstetrics, Odense Universitetshospital, Odense, Denmark.
Dorte GlintborgDepartment of Endocrinology, Odense Universitetshospital, Odense, Denmark.
Raquel Martin-IguacelDepartment of Infectious Diseases, Odense Universitetshospital, Odense, Denmark.
Isik Somuncu JohansenDepartment of Infectious Diseases, Odense Universitetshospital, Odense, Denmark.
Louise Lehmann ChristensenDepartment of Endocrinology, Odense Universitetshospital, Odense, Denmark.
Sanne JespersenDepartment of Infectious Diseases, Aarhus Universitetshospital, Aarhus, Denmark.
Eva HaugeDepartment of Obstetrics and Gynecology, Regionshospitalet Randers, Randers, Denmark.
Ioana Rotar1st Department of Obstetrics and Gynecology, University of Medicine and Pharmacy "Iuliu Hatieganu", Cluj Napoca, Romania.
Daniel Muresan1st Department of Obstetrics and Gynecology, University of Medicine and Pharmacy "Iuliu Hatieganu", Cluj Napoca, Romania.
Adriana BabanDepartment of Psychology, Universitatea Babes Bolyai, Cluj Napoca, Romania.
Diana TautDepartment of Psychology, Universitatea Babes Bolyai, Cluj Napoca, Romania.
Niamh M RedmondCERPOP (Centre for Epidemiology and Research in Population Health), EQUITY team, Inserm, University of Toulouse, Toulouse, France.ORCID 0000-0001-8814-3396
Partha BasuEarly Detection, Prevention & Infections Branch, International Agency for Research on Cancer (IARC), Lyon, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

IntroductionIn Europe, cervical cancer (CC) is the third most common gynaecologic cancer, and the second among women under the age of 45. CC screening uptake is highly variable across the region, and especially low among vulnerable groups.Current evidence suggests that HPV (Human Papilloma Virus) vaccination benefits women beyond traditional adolescent vaccination age groups, and so the HPV-FASTER approach has been proposed as a strategy to accelerate the elimination of CC in Europe. The HPV-FASTER-Implement implementation research project aims to evaluate strategies that integrate HPV-based screening with concomitant HPV vaccination (HPV-FASTER approach) for vulnerable groups aged 25-45 years, including migrants and sex workers in Spain and Sweden, women living with HIV and transgender men in Denmark, incarcerated women in Romania, and women living in deprived areas in France.MethodsTo assess the capacity of health systems to deliver combined HPV vaccination and HPV-based screening, we adapted the Cervical Cancer Screening Service Availability and Readiness Assessment (CervScreen-SARA) protocol and tools, considering also the WHO Effective Vaccine Management tool. This implementation research protocol includes three components: a desk review of CC screening and vaccination guidelines, and policies currently in place; screening, colposcopy, and vaccination services facility visits; and interviews with key meso- and macro-level stakeholders. Triangulation of the information allows the identification of strengths and areas of improvement in implementing the HPV-FASTER approach.ConclusionsThis implementation research protocol offers a structured approach to assess the readiness of health systems to deliver combined HPV vaccination and HPV-based CC screening to vulnerable populations, and will allow the tailoring of strategies to strengthen CC prevention services.

Indexed as

Early Detection of CancerHealth FacilitiesPapillomavirus InfectionsPapillomavirus VaccinesUterine Cervical NeoplasmsAdultFemaleHuman Papillomavirus VirusesHumansMass ScreeningMiddle AgedVaccinationVulnerable PopulationsPapillomavirus Vaccinescancer preventioncancer screeningcervical cancerhpvprevention

Identifiers

PMID42683830
PMCPMC13538996

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.